Do growth hormone peptides work? The trials stop before ageing

Growth hormone peptides work in the narrow sense that they do what they are designed to do: sermorelin, ipamorelin, CJC-1295 and tesamorelin push the body to release more of its own growth hormone [1][2]. What nobody has shown is the part they are sold for. When the Growth Hormone Research Society, an international group of hormone specialists, reviewed the evidence on using growth hormone or these peptides in older people, it concluded that their clinical use in older adults, alone or combined with testosterone, cannot be recommended until long-term studies with proper outcome measures exist [5].

The compounds split into two families that marketing tends to blur together. GHRH analogues - copies of the brain signal that tells the pituitary gland to release growth hormone - include sermorelin, tesamorelin and CJC-1295. Growth hormone secretagogues - drugs that imitate ghrelin, the hunger hormone, at a different receptor - include ipamorelin, hexarelin and the compounds sold as GHRP-2 and GHRP-6 [2].

A 2026 review that catalogued all of them sorted the compounds into tiers by how much human evidence each one has, running from a handful with regulatory-grade randomised trial data down to compounds with no human studies at all [2]. A separate 2026 review reached the same place from the orthopaedic side: the laboratory work is promising, and clinical trials are largely absent [1].

None of that covers what people actually buy the peptides for. The same review found the claimed gains in physique, performance and body recomposition remain uncertain, and no regulator has approved these compounds for those uses [2].

In older adults specifically, the answer has barely moved in more than twenty years. A 2003 review of the growth hormone axis and physical performance found no definite evidence that frail older people benefit from pushing growth hormone and IGF-1 back into the young-adult range, whether with growth hormone itself or with the releasing peptides [7]. A 2011 review of the same question concluded there was still not enough evidence for a clear therapeutic role [4].

The animal work does not line up neatly either. Giving old mice large doses of ghrelin, the hunger hormone these peptides imitate, increased their food intake, body weight and muscle strength [6]. Yet deleting the ghrelin receptor that ipamorelin-type peptides switch on, or blocking it with a drug, also improved muscle strength and endurance in ageing mice, animals aged 24 and 28 months set against 6-month-old young adults [8]. Removing the signal left lifespan unchanged in both studies [6][8].

Side effects are documented even where benefits are not. Among people using these compounds, the 2026 review lists:

• hormone and metabolic disturbances, including raised prolactin and cortisol, appetite changes and unstable blood sugar
• fluid retention
• muscle and joint aches
• reactions at the injection site [2]

The same review raises one concern it calls biologically plausible but unproven: because growth hormone and IGF-1 are signals that tell cells to grow, whether long-term use encourages existing cells to multiply has not been settled [2].

The rationale has a name: somatopause, the slow fall in growth hormone and in IGF-1 - a growth signal made mostly by the liver - that happens to nearly everyone with age [4][7]. Older bodies gain fat, lose muscle, tire sooner and lose strength. Adults whose pituitary gland has been damaged by disease show much the same pattern, so it was a fair question whether topping the hormone back up would undo the changes [4].

The reasoning has a problem, and the same review that lays out the idea names it: the hormone pattern of normal ageing is not the same as the pattern in pituitary disease, so the two situations may not respond to the same treatment [4]. Ageing lowers growth hormone mainly by changing how the brain signals the pituitary, rather than by breaking the gland itself [7].

The peptides act one step above that signal, which is why they are given instead of growth hormone itself [2]. Downstream, the IGF-1 signalling they switch on produces the repair effects seen in the laboratory, including the activation of satellite cells, the stem cells that rebuild damaged muscle fibres [1].

The ghrelin side is murkier. Ghrelin rises during fasting and during calorie restriction, the one intervention with a long record of extending life in animals, and that is the basis for treating the ghrelin pathway as a possible ageing target [3]. The mouse experiments that followed found better muscle function when the pathway was switched off, not on [8].

Almost everything above is a review or an expert statement rather than a fresh trial, which is itself the finding: there is not much primary human data to summarise [1][2][5].

The evidence does not apply to several groups:

• anyone with diagnosed growth hormone deficiency caused by pituitary disease, who is a different patient with a different treatment question [4]
• patients prescribed one of these compounds for an approved medical indication, which is not the same as taking it for ageing [2]
• women, since the 2026 mouse study used male animals only [8]
• people, in the case of both mouse studies, because results in mice have often failed to carry across [6][8]

The older-adult reviews date from 2003, 2009 and 2011, so they cannot account for anything published since [4][5][7]. None of the sources tested the specific sermorelin or ipamorelin protocols a clinic would actually prescribe, at the doses used, over the years people take them. The honest answer on long-term safety is that it has not been measured.

The two mouse studies also point in opposite directions depending on whether the ghrelin signal was dosed or removed [6][8], and neither was designed to test what these peptides do in a healthy middle-aged person.

Peptide therapy appears on the service list of a good many longevity clinics, and sermorelin and ipamorelin are among the compounds named most often. A first visit is usually a consultation plus blood work, after which a clinician decides whether to prescribe anything. These are prescription medicines, so that decision belongs with a doctor who can look at your own results.

The 2026 review was written partly to help clinicians work out what is happening when someone arrives already taking these compounds, frequently bought from unregulated suppliers where the contents, dose and purity of the product are not guaranteed [2]. Questions worth asking at that first appointment: which compound, what outcome it is meant to change, how that outcome will be measured, and what human evidence exists for that particular peptide.